Greenwich LifeSciences In... (GLSI)
Greenwich LifeSciences Statistics
Share Statistics
Greenwich LifeSciences has 13.14M shares outstanding. The number of shares has increased by 2.31% in one year.
| Shares Outstanding | 13.14M |
| Shares Change (YoY) | 2.31% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 8.81% |
| Shares Floating | 5.91M |
| Failed to Deliver (FTD) Shares | 670 |
| FTD / Avg. Volume | 2.06% |
Short Selling Information
The latest short interest is 484.6K, so 3.69% of the outstanding shares have been sold short.
| Short Interest | 484.6K |
| Short % of Shares Out | 3.69% |
| Short % of Float | 8.2% |
| Short Ratio (days to cover) | 21.41 |
Valuation Ratios
The PE ratio is -15.2 and the forward PE ratio is -16.01. Greenwich LifeSciences's PEG ratio is -0.9.
| PE Ratio | -15.2 |
| Forward PE | -16.01 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 20.17 |
| P/FCF Ratio | -20.86 |
| PEG Ratio | -0.9 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Greenwich LifeSciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.74, with a Debt / Equity ratio of 0.
| Current Ratio | 23.74 |
| Quick Ratio | 23.74 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.33% and return on capital (ROIC) is -139.21%.
| Return on Equity (ROE) | -1.33% |
| Return on Assets (ROA) | -1.27% |
| Return on Capital (ROIC) | -139.21% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2,963,934.33 |
| Employee Count | 3 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -6.15% in the last 52 weeks. The beta is 3.3, so Greenwich LifeSciences's price volatility has been higher than the market average.
| Beta | 3.3 |
| 52-Week Price Change | -6.15% |
| 50-Day Moving Average | 12.43 |
| 200-Day Moving Average | 13.88 |
| Relative Strength Index (RSI) | 48.95 |
| Average Volume (20 Days) | 32.51K |
Income Statement
| Revenue | n/a |
| Gross Profit | -3.61K |
| Operating Income | -9.33M |
| Net Income | -8.89M |
| EBITDA | -9.32M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.69 |
Balance Sheet
The company has 6.99M in cash and 0 in debt, giving a net cash position of 6.99M.
| Cash & Cash Equivalents | 6.99M |
| Total Debt | 0 |
| Net Cash | 6.99M |
| Retained Earnings | -50.36M |
| Total Assets | 5.83M |
| Working Capital | 4.98M |
Cash Flow
In the last 12 months, operating cash flow was -6.48M and capital expenditures 0, giving a free cash flow of -6.48M.
| Operating Cash Flow | -6.48M |
| Capital Expenditures | 0 |
| Free Cash Flow | -6.48M |
| FCF Per Share | -0.5 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GLSI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.66% |
| FCF Yield | -4.04% |
Analyst Forecast
The average price target for GLSI is $38, which is 211.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 211.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 89.29 |
| Piotroski F-Score | 2 |